Angion Completes Equity Financing and Appoints Senior Executives

Angion, a late-stage clinical biopharmaceutical company focused on kidney diseases and other acute organ injuries, announces the recent closing of a $35 million equity private placement.

Intuitive Venture PartnersJanuary 4, 2019angion, 2019

Entera Bio and Amgen Enter Strategic Research Collaboration in Inflammatory Disease and Other Serious Illnesses

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today that it has entered into a research collaboration and license agreement with Amgen in inflammatory disease and other serious illnesses.

Intuitive Venture PartnersDecember 11, 2018entera bio, 2018

Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) announced today that Patrick H. Griffin, M.D., F.A.C.P. has joined as the acting head of clinical development.

Intuitive Venture PartnersNovember 26, 2018innovate biopharmaceuticals, 2018

Angion Biomedica and Sinovant Sciences Enter into Collaboration and License Agreement to Develop BB3 in Greater China

Angion Biomedica and Sinovant Sciences today announced a collaboration and license agreement for BB3, which is shown to have improved renal function post-transplant.

Intuitive Venture PartnersNovember 12, 2018angion, 2018

Entera Bio Reports Positive Results from Study of Oral PTH in Patients with Hypoparathyroidism

Entera Bio Ltd. (NASDAQ: ENTX) announced today that it has received positive results from the first part of its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its oral parathyroid hormone (PTH) drug.

Intuitive Venture PartnersNovember 8, 2018entera bio, 2018

Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) announces it intends to present at the Jefferies 2018 London Healthcare Conference. The conference is being held on November 14-15, 2018.

Intuitive Venture PartnersOctober 31, 2018innovate biopharmaceuticals, 2018

Entera Bio Appoints Two New External Independent Members to the Board of Directors

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) announced today the appointment of Faith L. Charles and Miranda J. Toledano to the company’s board of directors, effective immediately.

Intuitive Venture PartnersOctober 2, 2018entera bio, 2018

Innovate Biopharmaceuticals Announces Participation at the Ladenburg Thalmann 2018 Healthcare Conference

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT), announced it intends to present at the Ladenburg Thalmann 2018 Healthcare Conference. The conference is being held on October 2, 2018, at the Sofitel Hotel in New York City.

Intuitive Venture PartnersOctober 1, 2018innovate biopharmaceuticals, 2018

Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Neurotrope, Inc. (NASDAQ: NTRP), announces that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018.

Intuitive Venture PartnersSeptember 27, 2018neurotrope, 2018

Entera Bio Appoints Dr. Arthur Santora as Chief Medical Officer

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced the appointment of Arthur C. Santora II, MD, PhD as its new Chief Medical Officer, effective immediately.

Intuitive Venture PartnersSeptember 21, 2018entera bio, 2018

Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome

Neurotrope Inc. (NASDAQ: NTRP) is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X").

pharmaceutical, alzheimersIntuitive Venture PartnersSeptember 5, 2018neurotrope, 2018

Pieris Pharmaceuticals Announces Dosing of First Patient in Phase I Combination Trial

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced today that it has dosed the first patient in the Company’s Phase 1 combination clinical trial of its lead proprietary immuno-oncology drug.

pharmaceuticalIntuitive Venture PartnersSeptember 4, 2018pieris, 2018

Entera Bio Reports Second Quarter 2018 Financial Results and Operating Update

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW) today announced its second quarter 2018 financial results and provided an operating update.

pharmaceuticalIntuitive Venture PartnersAugust 20, 2018entera bio, 2018

Innovate Biopharmaceuticals Reports Second Quarter 2018 Earnings and Key Corporate Highlights

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT) reported its second quarter 2018 financial results and key highlights.

Intuitive Venture PartnersAugust 15, 2018innovate biopharmaceuticals, 2018

ViewRay Announces Pricing of Public Offering of Common Stock

ViewRay, Inc. (NASDAQ: VRAY) today announced the pricing of an underwritten public offering of 16,216,217 shares of common stock.

Intuitive Venture PartnersAugust 14, 2018viewray, 2018

Neurotrope Provides Business Update and Reports Second Quarter 2018 Financial Results

Neurotrope, Inc. (NASDAQ: NTRP) today provided a business update outlining recent clinical development progress and other noteworthy events that occurred subsequent to the end of the quarter and unaudited financial results for the quarter ended June 30, 2018.

Intuitive Venture PartnersAugust 13, 2018neurotrope, 2018

Entera Bio Ltd. Announces Appointment of Mr. Gerald Lieberman as Chairman of the Board of Directors

Entera Bio Ltd. (NASDAQ: ENTX and ENTXW), announced today the appointment of Mr. Gerald Lieberman as the chairman of the board of directors, effective as of August 6, 2018.

READ MORE

Intuitive Venture PartnersAugust 9, 2018entera bio, 2018

Solbright and M2M Spectrum Networks Merge to Create Iota Communications, Inc.

Solbright Group, Inc. (OTC: SBRT) and M2M Spectrum Networks, LLC today announce the signing of a merger agreement creating the first publicly-traded, pure-play, fully-featured IoT network operating company in the U.S., Iota Communications, Inc. (“Iota”).

Intuitive Venture PartnersJuly 31, 2018iota communications, 2018

Innovate Biopharmaceuticals, Inc. added to membership of Russell 3000®, 2000® and the Russell Microcap® Indexes

Innovate Biopharmaceuticals Inc. (NASDAQ: INNT) announced today that it has been added as a member of the broad-market Russell 3000®, 2000® and Microcap® Indexes as part of the 2018 Russell indexes reconstitution.

Intuitive Venture PartnersJune 25, 2018innovate biopharmaceuticals, 2018

Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of Anna Kazanchyan, M.D.

Innovate Biopharmaceuticals, Inc. (“Innovate”) (NASDAQ: INNT) today announced the appointment of Saira Ramasastry, to its Board of Directors (Board).

Intuitive Venture PartnersJune 13, 2018innovate biopharmaceuticals, 2018